Immuron Ltd
Immuron Ltd (IMRN) is a small-cap biopharmaceutical company developing antibody-based products aimed mainly at enteric and infectious conditions. The company pursues a polyclonal antibody approach and advances programmes that may be used as oral or systemic prophylactics and therapeutics. For investors, key considerations are its early-stage pipeline, dependency on clinical and regulatory milestones and the need for ongoing funding — reflected in a market capitalisation of about $14.7m. Small-cap biotechs can offer meaningful upside around successful trials but carry heightened risks: clinical failures, regulatory delays, dilution from capital raises and limited trading liquidity. Before considering an investment, review the company’s latest financial reports, trial updates and regulatory filings, and assess your risk tolerance. This information is educational and not personal financial advice; returns are not guaranteed and the value of investments can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immuron's stock with a target price of $4, indicating strong growth potential.
Financial Health
Immuron Ltd is generating good revenue and maintaining a healthy profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMRN
Microbiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline catalysts
Clinical and regulatory milestones can shift market sentiment, but outcomes are uncertain and can cause significant volatility.
Technology focus
A polyclonal antibody approach targets infectious and gut conditions; technology may be differentiating but requires robust clinical proof.
Small-cap dynamics
With a market cap around $14.7m, shares may be thinly traded and sensitive to news; consider liquidity and funding risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
